ADEL: Funding, Investors & Team (Oct 2026)
The company is a spin-off from Asan Medical Center, University of Ulsan University, with a primary objective of developing therapeutic and diagnostic agents for neurological diseases, particularly Alzheimer's disease. In 2016, the company took significant steps toward formalizing its presence in the market by completing its incorporation and business registration processes. The year 2017 proved to be a milestone for the company as it obtained certification as a corporate-affiliated research institute, solidifying its position as a reputable research-driven organization. Additionally, it garnered recognition as a leading university start-up by the Ministry of SMEs and Startups, further boosting its credibility and potential for growth. The company has collaborated with Oscotech Co., Ltd. and partnered with various investors, including Kite Entrepreneurship Foundation, Stone Bridge Ventures Co., Ltd., Korea Development Bank, and Stick Ventures Co., Ltd., to jointly develop their projects.
ADEL has raised $2.4M across 1 funding round on record, the most recent an undisclosed round of $2.4M announced in Jun 2026.
That round is below the $8.1M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
ADEL Company Profile and Key Stats
Latest funding round on record: Jun 2026.
ADEL Funding Rounds
ADEL Founders and Leadership Team
No contact details are on record for this team yet.
ADEL Funding Compared to Other Biotechnology Startups
ADEL's latest round of $2.4M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like ADEL in Biotechnology and Seoul
Companies Similar to ADEL
ArcGen Bioscience is a biopharmaceutical development company
Lego Chem Bioscience , a company created by people with dreams and enthusiasm for global new drug…
April Bio is a drug development company that develops antibodies and long-acting biologics.
LabGenomics is a healthcare company specialized in molecular diagnostics.
Galaxy operates a pharmaceutical research and development company for the treatment of encephalopathy and…
SPARK BioPharma Co., Ltd. was established in Seoul National University in January 2016 based on the unique…
3billion was founded with the goal of ending the diagnostic odyssey of rare disease patients through…
Shaperon is a clinical-stage biotech company that develops inflammasome inhibitors.
SN BioScience provide nano-formulation screening services for small molecule, oligonucleotide (siRNA, DNA),…
M-Based develops new alternative material technologies using mushrooms. 🍄 We consider environmental…
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Turning biomass residues into fit-for-purpose microbial fertilizers, biostimulants and biocontrols.
ADEL Funding FAQs
What does ADEL do?
The company is a spin-off from Asan Medical Center, University of Ulsan University, with a primary objective of developing therapeutic and diagnostic agents for neurological diseases, particularly Alzheimer's disease. In 2016, the company took significant steps toward formalizing its presence in the market by completing its incorporation and business registration processes. The year 2017 proved to be a milestone for the company as it obtained certification as a corporate-affiliated research institute, solidifying its position as a reputable research-driven organization. Additionally, it garnered recognition as a leading university start-up by the Ministry of SMEs and Startups, further boosting its credibility and potential for growth. The company has collaborated with Oscotech Co., Ltd. and partnered with various investors, including Kite Entrepreneurship Foundation, Stone Bridge Ventures Co., Ltd., Korea Development Bank, and Stick Ventures Co., Ltd., to jointly develop their projects.
How much funding has ADEL raised?
ADEL has raised $2.4M across 1 round on record. The most recent is an undisclosed round of $2.4M announced in Jun 2026.
When did ADEL last raise funding?
ADEL's most recent funding round on record is an undisclosed round of $2.4M, announced in Jun 2026.
Who founded ADEL?
FundedIQ lists Adel Al (Founder) at ADEL.
Where is ADEL headquartered?
ADEL is based in Seoul, Seoul-t'ukpyolsi, South Korea.
How many employees does ADEL have?
ADEL is in the 11-50 employee band.
How does ADEL's funding compare to other Biotechnology startups?
ADEL's latest round of $2.4M is below the $8.1M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's ADEL Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for ADEL is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.